This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Reuters
reuters.com
did:plc:jbvnehrrdqoulco4rf5gxg5r
Moderna and Merck said that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%. Michele Gershberg has more.
2026-08-20T01:57:40.569Z